For instance, we found that EIF3F cooperates with STAT3 and exploited this finding to successfully target EIF3F-overexpressing human lung cancer cells with nifuroxazide, an FDA-approved oral anti-diarrheal agent that has been identified as an inhibitor of STAT3 [42]. This evidence concerns the gene STAT3 and lung carcinoma.